Page 2 - Metropolis Healthcare

Healthcare stocks rally up to 8% as Covid cases spurt in China, Japan

Reports suggest that Union Health Minister Mansukh Mandaviya will review the Covid-19 pandemic situation, in view of a spurt in COVID-19 cases in Japan, South Korea, Brazil, China and the US.

Multiple headwinds could act as margin tourniquet for diagnostics

Competitive pressures, valuations cap gains from current levels

Income Tax dept conducts searches at Metropolis Healthcare in Mumbai

The Income-tax department on Wednesday conducted searches at the premises of Mumbai-based Metropolis Healthcare that runs medical diagnostic centres as part of a tax evasion investigation, official sources said. The locations of the company in Mumbai are being covered, they said. A response from the company is awaited. The company is a prominent player in the medical tests and diagnostics business domain. It had last week reported a consolidated profit after tax of Rs 40.5 crore for the second quarter that ended September 30.

Here's why Mehul Kothari recommends buying Metropolis, Thyrocare Tech

According to the technical analyst from Anand Rathi, Metropolis Healthcare can rally to Rs 1,800, while Thyrocare Technologies can rise up to Rs 740.

Here's why Mehul Kothari recommends buying Raymond, Metropolis Healthcare

According to the technical analyst from Anand Rathi, Raymond can rally to Rs 1,100, while Metropolis Healthcare can surge to Rs 1,620.

Krsnaa Diagnostics, Metropolis hit 52-week; fall up to 14% in one month

In the past one year, these stocks have slipped between 48 per cent and 51 per cent, as compared to 3 per cent gain in the Sensex

Lots of interest in Metropolis, but we want a strategic fit: MD Ameera Shah

In a Q&A, the promoter and MD of the company talks about how the dynamics are changing in the diagnostics sector post Covid, and outlines her strategy for Metropolis 3.0

No plans to exit business, says Metropolis Healthcare promoters

"The company, its promoters and management team are committed to operating Metropolis Healthcare Ltd with the highest standards of medical science, stakeholder trust and customer engagement," the comp

No plans to exit business, clarify Metropolis Healthcare promoters

Metropolis Healthcare is continuously exploring various strategic options and investment

Metropolis tanks 27% in 1-mth on promoter stake sale buzz, latter clarifies

The promoters of Metropolis Healthcare on Monday after market hours clarified that they have no intention to exit the business.

Stocks to watch: Bajaj Finance, Zydus Lifesciences, Tata Steel, Amara Raja

Stocks to watch today: Bajaj Finance has raised fixed deposit rates by up to 20 basis points; Zydus Lifesciences will open its share buyback offer on June 23 and close on July 6.

Promoters have no intention to exit business: Metropolis Healthcare

Promoters are focused on strengthening the Metropolis brand, although it continuously keeps exploring various strategic options/investment opportunities

Sensex slips 215pts amid volatility post repo rate hike; ITC, RIL weigh

The RBI today raised the repo rate to 4.9 per cent, up from 4.4 per cent. The Central Bank also raised consumer price (CPI) or retail inflation forecast for FY23 to 6.7 per cent from 5.7 per cent.

Adani Group, Apollo in talks to buy a majority stake in Metropolis

Adani and Apollo's deal with Metropolis could be at least worth $1 billion or Rs 7,765 crore, given the market captalisation of the diagnostic chain

Sensex falls for 3rd day, dips 303 pts; Asian Paints sinks 8%; IT index 3%

CLOSING BELL: The broader markets, meanwhile, bled more with the BSE SmallCap index sliding nearly 3 per cent, and the BSE MidCap index falling close to 2 per cent

Stocks to Watch: Adani Ports, Strides, Metropolis, RITES, Zee, Balrampur

Stocks to Watch Today: Sugar and FMCG stocks likely to be in focus as govt limits sugar exports and exempts customs duty on agri cess. Apollo Hospitals, Bata, Coal India and Nalco to report results.

Amazon, Flipkart in talks to buy stake in $1 bn diagnostic chain Metropolis

Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa

Metropolis Healthcare to set up 1,800 collection centres in three years

The company is planning to add around 40 more Hitech centres during the current financial year

Metropolis Healthcare plunges 23% in two days on disappointing Q3 results

In Q4FY22, the company expects better profitability on account of higher QoQ volumes from large government contract and benefits of investments in digitization and marketing.

Metropolis Healthcare net profit dips 30% to Rs 41 cr in December quarter

Metropolis Healthcare on Friday said its net profit declined 29.69 per cent to Rs 41.2 crore for the third quarter ended December 31, 2021. The diagnostics chain had reported a net profit of Rs 58.6 core in the same period of previous fiscal. Revenues, however, increased to Rs 293.1 crore in the period under review as against Rs 274.7 crore in the same period of 2020-21 fiscal, Metropolis Healthcare said in a statement. "We have been able to grow our non-COVID revenue despite a sharp drop in volumes from a government contract. We have made increased investments in digital and marketing, manpower & customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a short-term phenomenon," Metropolis Healthcare Promoter and Managing Director Ameera Shah noted. The company has been able to successfully complete the acquisition of Hitech Diagnostics during the third quarter which will enable it to scale up business, improve the B2C revenue